System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Stephan Weidinger is an expert in Dermatology at University Hospital Schleswig-Holstein (Germany). As of October 2026, ScienceLeadR ranks Stephan Weidinger in the top 1% of experts worldwide for Dermatitis, Hypersensitivity and Skin Diseases, Eczematous. Stephan Weidinger has authored 581 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 4 of them ongoing. SLR score: 2,623 (community average: 125). How the SLR is computed.

LeadR Profile

Stephan Weidinger University Hospital Schleswig-Holstein Germany
2 623 ScienceLeadR Reputation 2623

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Immunology - Genetics - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1981 - 2026
Source: PubMed

University Hospital Schleswig-Holstein

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 581

Citations

Citations: 30 033 1st author: 83 Last author: 108 Unique author: 3

Main journals

J Invest Dermatol 61
Br J Dermatol 56
J Allergy Clin Immunol 48
Allergy 26
J Eur Acad Dermatol Venereol 25

Best Journals

Nat Rev Dis Primers 3
Lancet 2
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
OX40 Ligand/OX40 Axis as the Inflammatory Prequel in Atopic Dermatitis: A Narrative Review.
PMID 42823603 — skin, cells, ox40 ligand, dermatitis, therapeutics, ligands, dermatitis, atopic		Dermatol Ther (Heidelb)20260
Non-communicable inflammatory skin diseases comprise clinically meaningful distinct endotypes as identified by non-hypothesized integration of phenotypic and transcriptome data.
PMID 42685866 — skin, hypersensitivity, transcriptome, multiple chronic conditions, skin diseases, therapeutics		J Allergy Clin Immunol20260
Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).
PMID 42663863 — safety, dermatitis, dermatitis, atopic		Dermatol Ther (Heidelb)20260
Dermkielia cavawata sp. nov. gen. nov., Isolated From Plantar Eczema.
PMID 42635349 — skin, physiology, eczema, phenotype, phylogeny, spores		Mycoses20260
Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.
PMID 42593155 — registries, interleukin-13, sexually transmitted diseases, safety, dermatitis, dermatology, dermatitis, atopic		Acta Derm Venereol20260

Clinical Studies 26

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 3 10
N/A 9
Phase 2 6
Phase 2/Phase 3 1

By status:

Completed 15
Recruiting 5
Active not recruiting 3
No longer available 1
Terminated 1
Unknown 1

By type:

Interventional 18
Observational 7
Expanded Access 1

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 0
multicentricup10 18

Main Topics

Cohort/Consortium Investigators 16

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in participants aged 12 years and older with moderate to severe atopic dermatitis
2023-508096-36-00 — injections, safety, dermatitis, maintenance, aged, therapeutics, injections, subcutaneous, dermatitis, atopic		Phase 3Active not recruiting2024
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis
2025-522578-35-00 — safety, dermatitis, dermatitis, atopic, pharmacokinetics		Phase 2Recruiting2026
Determinants of Chronic Inflammatory Skin Disease Trajectories
NCT05928169 — skin, dermatitis, alopecia areata, pharmaceutical preparations, vitiligo, hidradenitis suppurativa, rosacea, skin diseases, hidradenitis, lichens, prurigo, therapeutics, lichen planus, psoriasis, alopecia, dermatitis, atopic		N/ARecruiting2023
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real World Setting
NCT05139836 — skin, dermatitis, cohort studies, tablets, adolescent, therapeutics, dermatitis, atopic		N/AActive not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS